Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares stood at 0.37 million during the latest session, with the company’s beta value hitting -0.50. At the last check today, the stock’s price was $19.98, to imply a decrease of -0.65% or -$0.13 in intraday trading. The SMMT share’s 52-week high remains $33.89, putting it -69.62% down since that peak but still an impressive 89.49% since price per share fell to its 52-week low of $2.10. The company has a valuation of $14.74B, with an average of 2.54 million shares in intraday trading volume over the past 10 days and average of 2.49 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Summit Therapeutics Inc (SMMT), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give SMMT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.07.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
After registering a -0.65% downside in the latest session, Summit Therapeutics Inc (SMMT) has traded red over the past five days. The 5-day price performance for the stock is 4.12%, and -7.50% over 30 days. With these gigs, the year-to-date price performance is 11.96%. Short interest in Summit Therapeutics Inc (NASDAQ:SMMT) saw shorts transact 21.63 million shares and set a 9.05 days time to cover.
The extremes give us $32 and $42 for target low and target high price respectively. As such, SMMT has been trading -110.21% off suggested target high and -60.16% from its likely low.
Summit Therapeutics Inc (SMMT) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -10.52% for the past 5-year period. While 2025 is set for a -37.90% return in earnings, projections for the next 5 years are at -28.83% annually.
SMMT Dividends
Summit Therapeutics Inc has its next earnings report out on 2025-Feb-23. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Summit Therapeutics Inc insiders hold 84.36% of total outstanding shares, with institutional holders owning 12.91% of the shares at 82.60% float percentage. In total, 12.91% institutions holds shares in the company, led by BAKER BROS. ADVISORS LP. As of 2024-06-30, the company held over 23.22 million shares (or 3.2804% of shares), all amounting to roughly $181.13 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 8.82 million shares, or about 1.2566% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $68.78 million.
We also have Vanguard Total Stock Market Index Fund and SPDR(R) S&P(R) Biotech ETF as the top two Mutual Funds with the largest holdings of the Summit Therapeutics Inc (SMMT) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 3.4 shares. This is just over 0.46% of the total shares, with a market valuation of $67.72 million. Data from the same date shows that the other fund manager holds a little less at 3.32, or 0.45% of the shares, all valued at about 66.02 million.
